medical director and Lynette Herring as the business manager. Research publications The institute has provided funding for more than 80 Scientific publications concerned with psychedelic drug research. Cancer distress One supported research study found that a single dose of psilocybin significantly reduced anxiety and depressive symptoms in cancer patients. The institute then funded two larger clinical trials of the same treatment at New York University and Johns Hopkins University, which is expected to be published in 2016. Following that, the institute will be supporting an FDA Phase 3 study as a step toward gaining FDA approval of psilocybin for the treatment of anxiety and depression in cancer patients. Addiction Five scientific articles on Heffter-supported treatment of addictions with psilocybin have been published. Two recent small pilot studies on alcohol and smoking addiction showed significant positive results. As of early 2016, a large clinical trial is underway at New York University for alcohol dependence and at Johns Hopkins University for smoking. Two earlier studies on the treatment of heroin addiction with ketamine also showed a significant benefit. Spirituality Several Heffter-supported studies on Spiritual experiences and practices involving ayahuasca and psilocybin have been published. Neuroscience research There have been more than 70 scientific publications resulting from Heffter-supported neuroscience research, mostly from the Heffter Research Center at the University of Zurich, where one of the board members, Dr. Franz Vollenweider is the principal investigator. One of these studies found that psilocybin inhibits the processing of negative emotions in the brain. See also Multidisciplinary Association for Psychedelic Studies Beckley Foundation Arthur Heffter References External links Heffter Research Institute website Psychedelic drug research 501(c)(3) organizations